Assenagon Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $142M | Buy |
8,445,992
+2,462,064
| +41% | +$41.3M | 0.21% | 90 |
|
|
2025
Q1 | $92M | Buy |
5,983,928
+4,824,247
| +416% | +$74.1M | 0.15% | 107 |
|
|
2024
Q4 | $25.6M | Sell |
1,159,681
-230,166
| -17% | -$5.07M | 0.04% | 296 |
|
|
2024
Q3 | $25M | Buy |
1,389,847
+985,845
| +244% | +$17.8M | 0.05% | 267 |
|
|
2024
Q2 | $6.57M | Sell |
404,002
-646,697
| -62% | -$10.5M | 0.01% | 526 |
|
|
2024
Q1 | $14.8M | Buy |
1,050,699
+471,137
| +81% | +$6.65M | 0.04% | 318 |
|
|
2023
Q4 | $6.05M | Buy |
579,562
+507,568
| +705% | +$5.3M | 0.02% | 551 |
|
|
2023
Q3 | $734K | Sell |
71,994
-1,768,279
| -96% | -$18M | ﹤0.01% | 1087 |
|
|
2023
Q2 | $13.9M | Buy |
+1,840,273
| New | +$13.9M | 0.05% | 276 |
|
|
2023
Q1 | – | Sell |
-1,036,449
| Closed | -$9.45M | – | 1459 |
|
|
2022
Q4 | $9.45M | Buy |
1,036,449
+121,768
| +13% | +$1.11M | 0.03% | 363 |
|
|
2022
Q3 | $7.38M | Buy |
914,681
+381,618
| +72% | +$3.08M | 0.03% | 385 |
|
|
2022
Q2 | $4.01M | Sell |
533,063
-129
| -0% | -$970 | 0.01% | 588 |
|
|
2022
Q1 | $5.01M | Sell |
533,192
-1
| -0% | -$9 | 0.01% | 503 |
|
|
2021
Q4 | $4.27M | Buy |
533,193
+33,019
| +7% | +$264K | 0.01% | 541 |
|
|
2021
Q3 | $4.87M | Buy |
+500,174
| New | +$4.87M | 0.02% | 415 |
|